Skip to main content
. Author manuscript; available in PMC: 2020 Jan 2.
Published in final edited form as: J Clin Immunol. 2019 May 14;39(4):440–447. doi: 10.1007/s10875-019-00640-5

Table 2.

Comparison of pulmonary complications between CVID and XLA

Diagnosis
N (%)
CVID
N = 749
XLA
N = 320
OR 95% CI P value
ILD (%) 107 (14.3) 7 (2.2) 7.45 (3.4–16.2) < 0.001
URT (%) 423 (56.5) 60 (18.8) 5.62 (4.1–7.7) < 0.001
Sinusitis (%) 576 (76.9) 156 (48.8) 3.5 (2.7–4.6) < 0.001
Bronchiectasis (%) 101 (13.5) 27 (8.4) 1.69 (1.1–2.6) 0.02
Pneumonia (%) 474 (63.3) 157 (49.1) 1.79 (1.4–2.3) < 0.001
Asthma (%) 234 (31.2) 33 (10.3) 3.95 (2.7–5.8) < 0.001

ILD interstitial lung disease, URT upper respiratory tract infection